Skip to main content

Table 1 Characteristics of patients

From: The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

Variable

N = 52

n

%

Sex

 Male

31

59.6

 Female

21

40.4

Age, years

 Median (range)

66 (40–80)

Performance status WHO

 0

38

73.1

 1

14

26.9

Primary site

 Colon

28

53.8

 Rectum

24

46.2

Metastases

 Synchronous

18

34.6

 Metachronous

34

65.4

Nunmer of metastatic site

 1

37

71.2

  >1

15

28.8

Metastaic sites

 Liver

30

57.7

 Liver only

16

30.8

 Lung

20

38.5

 Peritoneum

9

9.6

 Lymph nodes

5

17.3

Prior treatment

 Adjuvant chemotherapya

20

38.5

 Surgeryb

35

67.3

 Radiotheray

0

0

KRAS status

 Wild type

24/43

55.8

 Mutant type

19/43

44.2

  1. N total number of patients, n number of patients, WHO World Health Organization
  2. aChemotherapy with fluoropyrimidine. No patients received oxaliplatin-based adjuvant chemotherapy
  3. bResection of primary site